SCHEMBL10093504

SCHEMBL10093504

CC(=O)N(CCOCCOc1ccc(C(C)(C)CC(C)(C)C)cc1)Cc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 6/20 0.56
▸ MEN1 O00255 5/20 0.56
▸ SMN1; SMN2 Q16637 4/20 0.56
▸ LMNA P02545 4/20 0.56
▸ TSHR P16473 4/20 0.56
▸ ALDH1A1 P00352 4/20 0.56
▸ CYP3A4 P08684 3/20 0.56
▸ TDP1 Q9NUW8 3/20 0.56
▸ APAF1 O14727 3/20 0.56
▸ USP2 O75604 3/20 0.56
▸ TP53 P04637 3/20 0.56
▸ MAPT P10636 3/20 0.56
▸ RAD52 P43351 3/20 0.56
▸ ERBB2 P04626 2/20 0.56
▸ FYN P06241 2/20 0.56
▸ CHRM2 P08172 2/20 0.56
▸ CHRM4 P08173 2/20 0.56
▸ CHRM5 P08912 2/20 0.56
▸ ADRA2A P08913 2/20 0.56
▸ HSPD1 P10809 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14950044 0.91 KMT2A (0.58) KMT2AMEN1SMN1; SMN2LMNATSHR
SCHEMBL10093501 0.85 LMNA (0.50) KMT2AMEN1SMN1; SMN2LMNATSHR
SCHEMBL16326281 0.83 TSHR (0.61) KMT2AMEN1SMN1; SMN2LMNATSHR
Hydrochloric Acid SCHEMBL426559 0.82 TSHR (0.60) KMT2AMEN1SMN1; SMN2LMNATSHR
SCHEMBL17927915 0.82 LMNA (0.46) KMT2AMEN1SMN1; SMN2LMNATSHR
SCHEMBL10093502 0.79 LMNA (0.44) KMT2AMEN1SMN1; SMN2LMNATSHR
SCHEMBL26657537 0.76 SMN1; SMN2 (0.67) KMT2AMEN1SMN1; SMN2LMNATSHR
SCHEMBL9269061 0.75 NPC1 (0.51) KMT2AMEN1LMNATSHRACHE
SCHEMBL4288920 0.75 SMN1; SMN2 (0.63) KMT2AMEN1SMN1; SMN2LMNATSHR
SCHEMBL171239 0.75 SMN1; SMN2 (0.59) KMT2AMEN1SMN1; SMN2LMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101163-B2 Transdermal compositions MICRODERMIS CORPORATION (US) 2012-01-24 — — US disclosed
US-7893285-B2 Transdermal compositions MICRODERMIS CORPORATION (US) 2011-02-22 — — US disclosed
US-20100227929-A1 TRANSDERMAL COMPOSITIONS DRS. SOLUTIONS, LLC (US) 2010-09-09 — — US disclosed
US-20100203005-A1 TRANSDERMAL COMPOSITIONS DRS. SOLUTIONS, LLC (US) 2010-08-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100203005-A1 TRANSDERMAL COMPOSITIONS S100A10, TMSB10, FFAR3 KMT2A 4309/4885MEN1 2596/4885SMN1; SMN2 4798/4885
US-20100227929-A1 TRANSDERMAL COMPOSITIONS S100A10, TMSB10, FFAR3 KMT2A 4309/4885MEN1 2596/4885SMN1; SMN2 4798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback